TerminatedPhase 4NCT04316494
Hydroxychloroquine in ANCA Vasculitis Evaluation
Studying Anti-neutrophil cytoplasmic antibody-associated vasculitis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Guy's and St Thomas' NHS Foundation Trust
- Principal Investigator
- David D'CruzGuy's and St Thomas' NHS Foundation Trust
- Intervention
- Hydroxychloroquine(drug)
- Enrollment
- 43 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2020 – 2025
Study locations (18)
- Royal Berkshire NHS Foundation Trust, Reading, Berkshire, United Kingdom
- Cambridge University Hospitals NHS Foundation Trust, Cambridge, Cambridgeshire, United Kingdom
- East and North Hertfordshire NHS Trust, Stevenage, Hertfordshire, United Kingdom
- NHS Highland, Inverness, Inverness-shire, United Kingdom
- University Hospitals of Leicester NHS Trust, Leicester, Leicestershire, United Kingdom
- Liverpool University Hospitals NHS Foundation Trust, Liverpool, Merseyside, United Kingdom
- Royal United Hospitals Bath NHS Foundation Trust, Bath, Somerset, United Kingdom
- Surrey and Sussex Healthcare NHS Trust, Redhill, Surrey, United Kingdom
- University Hospitals Sussex NHS Foundation Trust, Brighton, Sussex, United Kingdom
- Cardiff & Vale University Health Board, Cardiff, United Kingdom
- Epsom and St Helier University Hospitals NHS Trust, Epsom, United Kingdom
- Cwm Taf Morgannwg University Health Board, Llantrisant, United Kingdom
- Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom
- King's College Hospital NHS Foundation Trust, London, United Kingdom
- Imperial College Healthcare NHS Trust, London, United Kingdom
- +3 more locations on ClinicalTrials.gov
Collaborators
Medical Research Council
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04316494 on ClinicalTrials.govOther trials for Anti-neutrophil cytoplasmic antibody-associated vasculitis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07556484Pharmacokinetics Of Emulsified Avacopan Applied By NG TubeMayo Clinic
- RECRUITINGEARLY PHASE1NCT07507201Allogeneic CD19/BCMA CAR-T for B Cell-Related Autoimmune DiseaseThe Children's Hospital of Zhejiang University School of Medicine
- RECRUITINGNCT07258524PET Assessment of Disease Activity and Cardiovascular Disease Risk in ANCA-associated VasculitisUniversity of Edinburgh
- RECRUITINGPHASE1NCT07315087CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune DiseasesInstitute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE2NCT07160608Safety and Efficacy of Tarperprumig in Adult Participants With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated VasculitisAlexion Pharmaceuticals, Inc.
- RECRUITINGPHASE3NCT07168161BDB-001 Phase III Trial in ANCA-Associated VasculitisStaidson (Beijing) Biopharmaceuticals Co., Ltd
- RECRUITINGPHASE3NCT06983821Safe Effective Therapy With Low-Dose Glucocorticoid in ANCA-Associated Vasculitis (SAFE-LOW)Ottawa Hospital Research Institute
- RECRUITINGNCT07151521(68)Ga-FAPI PET/CT in Patients With ANCA-associated VasculitisRuijin Hospital
See all trials for Anti-neutrophil cytoplasmic antibody-associated vasculitis →